tiprankstipranks
Starpharma Holdings Limited (AU:SPL)
ASX:SPL

Starpharma Holdings Limited (SPL) Share Price & Analysis

3 Followers

SPL Stock Chart & Stats

Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.12 - AU$0.53
Previous CloseAU$0.13
Volume52.58K
Average Volume (3M)247.68K
Market Cap
AU$53.57M
Enterprise ValueAU$11.84M
Total Cash (Recent Filing)AU$49.92M
Total Debt (Recent Filing)AU$8.19M
Price to Earnings (P/E)-6.3
Beta0.55
Aug 21, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding412,040,620
10 Day Avg. Volume586,196
30 Day Avg. Volume247,684
Standard Deviation0.14
R-Squared0.16
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)0.65
Price to Sales (P/S)145.03
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

7.46%2.43%<0.01%90.11%
7.46%
Insiders
<0.01% Other Institutional Investors
90.11% Public Companies and
Individual Investors

SPL FAQ

What was Starpharma Holdings Limited’s price range in the past 12 months?
Starpharma Holdings Limited lowest share price was AU$0.12 and its highest was AU$0.53 in the past 12 months.
    What is Starpharma Holdings Limited’s market cap?
    Currently, no data Available
    When is Starpharma Holdings Limited’s upcoming earnings report date?
    Starpharma Holdings Limited’s upcoming earnings report date is Aug 21, 2024 which is in 106 days.
      How were Starpharma Holdings Limited’s earnings last quarter?
      Starpharma Holdings Limited released its earnings results on Feb 27, 2024. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
        Is Starpharma Holdings Limited overvalued?
        According to Wall Street analysts Starpharma Holdings Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Starpharma Holdings Limited pay dividends?
          Starpharma Holdings Limited does not currently pay dividends.
          What is Starpharma Holdings Limited’s EPS estimate?
          Starpharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Starpharma Holdings Limited have?
          Starpharma Holdings Limited has 412,040,620 shares outstanding.
            What happened to Starpharma Holdings Limited’s price movement after its last earnings report?
            Starpharma Holdings Limited reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Starpharma Holdings Limited?
              Currently, no hedge funds are holding shares in AU:SPL
              ---

              Starpharma Holdings Limited Stock Smart Score

              5
              Neutral
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Technicals

              SMA
              Negative
              20 days / 200 days
              Momentum
              -74.21%
              12-Months-Change

              Fundamentals

              Return on Equity
              -22.01%
              Trailing 12-Months
              Asset Growth
              -23.32%
              Trailing 12-Months

              Company Description

              Starpharma Holdings Limited

              Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. Its programs include: VivaGel portfolio, Drug delivery and Agrochemicals, which develops a number of products internally and others via commercial partnerships. Its product is VivaGel, a gel-based formulation of a proprietary dendrimer and is under clinical development for the treatment and prevention of bacterial vaginosis and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Starpharma Holdings Limited
              BioNTech SE
              Arcturus Therapeutics
              Exelixis
              Inovio Pharmaceuticals
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis